A Phase 4 Clinical Study of Brodalumab
NCT04183881
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
138
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis Vulgaris
Psoriatic Arthritis
Pustular; Psoriasis, Palmaris Et Plantaris
Psoriatic Erythroderma
Interventions
DRUG:
Brodalumab 210mg SC
Sponsor
Kyowa Kirin Co., Ltd.